Stock AMYLIN PHARMACEUTICALS LLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Amylin Pharmaceuticals LLC

Equities

US0323461089

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Amylin Pharmaceuticals LLC
2012 Bristol Myers Squibb Co. : Bristol-Myers executive charged with insider trading RE
2012 BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion RE

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Amylin Pharmaceuticals, Inc. : Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin
PU
Bristol Myers Squibb Co. : Bristol-Myers executive charged with insider trading
RE
BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion
RE
GlaxoSmithKline plc : Exclusive: GSK set for Human Genome takeover - sources
RE
GlaxoSmithKline plc : GSK in weekend talks to buy Human Genome: sources
RE
Forest Laboratories, Inc. : Exclusive: Icahn offered to settle with Forest before battle
RE
Exclusive: Icahn offered to settle with Forest before battle
RE
Amylin Pharmaceuticals, Inc. : Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Amylin Pharmaceuticals, Inc.
PR
Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
BU
Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
PR
Amylin Pharmaceuticals, Inc. : Ryan & Maniskas, LLP Announces Investigation of Amylin Pharmaceuticals, Inc.
BU
SANOFI : Icahn return on Amylin tops 35 percent
RE
Bristol Myers Squibb Co. : Bristol's patent woes persist despite Amylin buy
RE
Amylin Pharmaceuticals, Inc. : Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amylin Pharmaceuticals Inc.
BU
SANOFI : AstraZeneca hungry to refill medicine cabinet
RE
SANOFI : Bristol-Myers to buy Amylin for about $5.3 billion
RE
Amylin Pharmaceuticals, Inc. : New Clinical Data Analyses Show Metreleptin Reduced Blood Glucose and Triglyceride Levels in Patients with Rare Forms of Lipodystrophy
BU
Amylin Pharmaceuticals, Inc. : SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range
BU
Amylin Pharmaceuticals, Inc. : BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes
BU
Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present Data on BYDUREON™, BYETTA® and SYMLIN® at the American Diabetes Association 2012 Meeting
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Amylin Pharmaceuticals LLC